These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21363913)

  • 1. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation.
    Nassar T; Attili-Qadri S; Harush-Frenkel O; Farber S; Lecht S; Lazarovici P; Benita S
    Cancer Res; 2011 Apr; 71(8):3018-28. PubMed ID: 21363913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption.
    Attili-Qadri S; Karra N; Nemirovski A; Schwob O; Talmon Y; Nassar T; Benita S
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17498-503. PubMed ID: 24101508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
    Feng SS; Mei L; Anitha P; Gan CW; Zhou W
    Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.
    Choi YH; Suh JH; Lee JH; Cho IH; Lee MG
    J Pharm Pharmacol; 2010 Aug; 62(8):1084-8. PubMed ID: 20663044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin.
    Yan YD; Kim DH; Sung JH; Yong CS; Choi HG
    Int J Pharm; 2010 Oct; 399(1-2):116-20. PubMed ID: 20727390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated poly(anhydride) nanoparticles for oral delivery of docetaxel.
    Ruiz-Gatón L; Espuelas S; Larrañeta E; Reviakine I; Yate LA; Irache JM
    Eur J Pharm Sci; 2018 Jun; 118():165-175. PubMed ID: 29597043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical characterization and in vivo evaluation of solid self-nanoemulsifying drug delivery system for oral administration of docetaxel.
    Quan Q; Kim DW; Marasini N; Kim DH; Kim JK; Kim JO; Yong CS; Choi HG
    J Microencapsul; 2013; 30(4):307-14. PubMed ID: 23101936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation.
    Yin YM; Cui FD; Mu CF; Choi MK; Kim JS; Chung SJ; Shim CK; Kim DD
    J Control Release; 2009 Dec; 140(2):86-94. PubMed ID: 19709639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
    Kuppens IE; Bosch TM; van Maanen MJ; Rosing H; Fitzpatrick A; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):72-8. PubMed ID: 15316750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-administration with cell penetrating peptide enhances the oral bioavailability of docetaxel-loaded nanoparticles.
    Bu X; Zhu T; Ma Y; Shen Q
    Drug Dev Ind Pharm; 2015 May; 41(5):764-71. PubMed ID: 24669977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats.
    Lee JH; Lee A; Oh JH; Lee YJ
    Biopharm Drug Dispos; 2012 Nov; 33(8):474-86. PubMed ID: 22936118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats.
    Lee JH; Oh JH; Lee YJ
    Xenobiotica; 2011 Sep; 41(9):797-804. PubMed ID: 21561320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
    van Waterschoot RA; Lagas JS; Wagenaar E; van der Kruijssen CM; van Herwaarden AE; Song JY; Rooswinkel RW; van Tellingen O; Rosing H; Beijnen JH; Schinkel AH
    Cancer Res; 2009 Dec; 69(23):8996-9002. PubMed ID: 19920203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats.
    Ben Reguiga M; Bonhomme-Faivre L; Farinotti R
    J Pharm Pharmacol; 2007 Mar; 59(3):401-8. PubMed ID: 17331344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier.
    Zhao X; Zhao Y; Geng L; Li X; Wang X; Liu Z; Wang D; Bi K; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Dec; 879(31):3721-7. PubMed ID: 22035980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles.
    Esmaeili F; Dinarvand R; Ghahremani MH; Ostad SN; Esmaily H; Atyabi F
    Anticancer Drugs; 2010 Jan; 21(1):43-52. PubMed ID: 19809300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect.
    Seo YG; Kim DH; Ramasamy T; Kim JH; Marasini N; Oh YK; Kim DW; Kim JK; Yong CS; Kim JO; Choi HG
    Int J Pharm; 2013 Aug; 452(1-2):412-20. PubMed ID: 23707964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake.
    Cho HJ; Park JW; Yoon IS; Kim DD
    Int J Nanomedicine; 2014; 9():495-504. PubMed ID: 24531717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting.
    Tiantian Y; Wenji Z; Mingshuang S; Rui Y; Shuangshuang S; Yuling M; Jianhua Y; Xinggang Y; Shujun W; Weisan P
    Int J Pharm; 2014 Aug; 471(1-2):245-57. PubMed ID: 24858386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice.
    Moreno D; Zalba S; Navarro I; Tros de Ilarduya C; Garrido MJ
    Eur J Pharm Biopharm; 2010 Feb; 74(2):265-74. PubMed ID: 19883755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.